Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients who have not previously received drug treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy:
When used as initial therapy in patients who have not previously received drug treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily.
The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin.
In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin previously taken or an appropriately titrated dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate.
In patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate.
When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia.
The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because any change may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet.
Renal impairment
No dosage adjustment is necessary in patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2, without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR < 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) decreases to < 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Older adults
Because metformin is excreted through the kidneys and renal function tends to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
Improvement of glycemic control in adults with type 2 diabetes mellitus
Type 2 diabetes
impaired blood sugar control
cardiovascular disease
cardiovascular risk factors
View approved original textHide original text
This medication is used to assist in blood sugar control for adult patients with type 2 diabetes who take dapagliflozin and metformin together. It is effective as an adjunct to dietary and exercise therapy, particularly suitable for patients whose blood sugar is not adequately controlled. However, patients with cardiovascular diseases or risks should use it cautiously after consulting a specialist. Overall, this medication helps improve blood sugar management in type 2 diabetes.
How to take
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients who have not previously received drug treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy:
When used as initial therapy in patients who have not previously received drug treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily.
The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin.
In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin previously taken or an appropriately titrated dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate.
In patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate.
When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia.
The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because any change may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet.
Renal impairment
No dosage adjustment is necessary in patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2, without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR < 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) decreases to < 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Older adults
Because metformin is excreted through the kidneys and renal function tends to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
Precautions
This medication contains metformin and dapagliflozin, which are diabetes treatments.
Though rare, a serious condition called lactic acidosis can occur while taking this medication, so it should not be used in cases of impaired kidney function or severe infections, or dehydration.
Furthermore, caution is necessary when used in conjunction with insulin or sulfonylureas, as hypoglycemia may occur.
Patients with moderate or severe impaired kidney function, heart failure, acute myocardial infarction, sepsis, or acute diseases with cardiovascular collapse should also avoid this medication.
Patients scheduled for tests using iodine contrast agents should stop taking this medication 48 hours prior to the test and begin again only after ensuring normal kidney function post-test.
Pregnant or breastfeeding women should not use this medication, and patients with genetic issues such as lactose intolerance should also refrain from using it.
Elderly patients or those with decreased kidney function should have their kidney function closely evaluated before taking this medication, and kidney function, blood pressure, and fluid status should be monitored regularly during treatment.
This medication may cause reduced fluid volume or low blood pressure due to increased urination, so caution is advised for patients with symptoms of dehydration or low blood pressure.
Genital infections or urinary infections may occur during treatment; if related symptoms arise, consult a doctor immediately.
The metformin component can cause vitamin B12 deficiency, so blood serum vitamin B12 levels should be checked during prolonged use.
Excessive alcohol consumption may elevate the risk of side effects from this medication, so avoiding alcohol during treatment is recommended.
This medication may interact with other drugs, so dosage adjustments and monitoring are necessary according to medical advice, especially when used with diuretics, antihypertensives, insulin, etc.
In case of overdose, immediate medical attention should be sought, and patients with impaired kidney function may require dialysis treatment.
Finally, the safety of this medication has not been established in children, and caution is needed as dizziness may occur when driving or operating machinery.
Side effects
Severe lactic acidosis
severe hypoglycemia
vulvovaginitis
balanitis and related genital infections
urinary tract infections
fungal infections
hypoglycemia
decreased fluid volume
thirst
diabetic ketoacidosis
Show 84 moreCollapse
dizziness
constipation
dry mouth
back pain
dysuria
polyuria
nocturia
vulvar pruritus
genital pruritus
increased hematocrit
reduced renal creatinine clearance
dyslipidemia
increased serum creatinine
increased blood urea
weight loss
ketoacidosis
urosepsis
pyelonephritis
acute kidney injury
renal dysfunction
rash
diarrhea
nausea
vomiting
decreased vitamin B12
Guillain-Barré syndrome
bacterial pneumonia
sialadenitis
tendinitis
chest pain
thermal burn
wrist fracture
gastrointestinal stromal tumor
malignant neoplasm of the lung
uterine fibroid
atrial fibrillation
acute cholecystitis
upper abdominal pain
dyspepsia
abdominal discomfort
abdominal pain
gastric ulcer
irritable bowel syndrome
salivary gland mass
toothache
headache
facial paralysis
peripheral neuropathy
paresthesia
drowsiness
tremor
nasopharyngitis
pharyngitis
adenoviral conjunctivitis
shingles
pneumonia
rhinitis
increased alanine aminotransferase
increased blood glucose
arthralgia
myalgia
fibromyalgia
osteoarthritis
osteochondrosis
limb pain
periarticular inflammation
tendinitis
trigger finger
weakness
fatigue
peripheral edema
edema
pain
vitamin D deficiency
hyperglycemia
urethral syndrome
cough
hyperventilation
skin abrasions
pruritus
palpitations
insomnia
type 2a hyperlipidemia
sensorineural hearing loss
Not everyone experiences these, and they can vary from person to person.
Storage
This medication may be sensitive to air or humidity, so it should be stored in a tightly closed container. The recommended storage temperature is room temperature between 1 to 30 degrees Celsius. This will help maintain the effectiveness and safety of the medication for a long time.
Appearance and packaging
Appearance
Pink, double-sided convex oval film-coated tablet
Package unit
30 tablets/bottle
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.